Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • Eleven Minutes
    • Priced Out
    • Data Grab
    • Memory Gaps
    • Growing Up Scared
    • Denied
    • Opioid Settlement Tracking
    • Guns, Race, and Profit
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email
  • Add Us to Google

Wednesday, Nov 18 2026 UPDATED 9:24 AM

Full Issue

Leukemia Vaccine Succeeds In Pivotal Trial

The trial showed a 41% reduction in risk of death for patients with acute myeloid leukemia who received the galinpepimut-S (GPS) vaccine, The Washington Post reported. Plus, the FDA anticipates the safety review of the abortion pill mifepristone to be finished by March.

The Washington Post: Leukemia Vaccine Passes Key Trial, Adding To Breakthrough Year For Cancer Drugs

A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced Tuesday, marking another positive result in a breakthrough year for cancer vaccines. (Wu, 11/17)

On the abortion pill —

Bloomberg: Abortion Pill Mifepristone Safety Review By FDA Set For March 2027 Completion

US health officials anticipate they will complete a report on the safety of the abortion drug mifepristone by next March, according to an update on the Food and Drug Administration’s website Tuesday. The FDA is using claims data from federal and private health insurance plans to compare the safety of mifepristone use, in combination with another drug called misoprostol, to surgical abortion. The agency expects to obtain the results from its analysis next month. (Edney, 11/17)

More pharma and tech developments —

MedPage Today: FDA Wants Liquid Statin Off Shelves

The FDA wants a liquid formulation of simvastatin (FloLipid) withdrawn from the market, though the agency is giving the drugmaker an opportunity for a hearing. Approval of simvastatin oral suspension is at risk because Salerno Pharma "has repeatedly failed to file required annual reports" to the FDA, according to a notice in the Federal Register. (Lou, 11/17)

The New York Times: Fearing Chinese Rivals, U.S. Biotech Adopts A New Norm: Share Nothing

It used to be that companies and scientists with ideas for new drugs couldn’t wait to announce their discoveries at meetings, in preprints and on their websites. That is changing. Researchers at the biotechnology firm Alnylam Pharmaceuticals have an unwritten policy: Do not reveal early-stage studies or discuss unpublished data, according to its founding chief executive, Dr. Christoph Westphal. (Kolata, 11/17)

Stat: New Startup Wants To Treat Sickle Cell Anemia Without Gene Therapy 

For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks. Biotech entrepreneur Romesh Subramanian thinks he might have one. (Mast, 11/17)

The New York Times: What Can Genes Reveal About Chronic Pain?

Nearly everyone knows someone living with chronic pain. Yet this condition remains notoriously difficult to measure, explain or treat. It can follow an acute injury or arrive unprompted, often evading medical scans and leaving patients without the visible evidence that might convince others their pain is real. And doctors still struggle to understand why pain lingers indefinitely in some bodies and dissipates in others. (Baumgaertner Nunn, 11/17)

The New York Times: Does This Man Have A Right To The Data From His Own Brain?

On a recent Thursday, J. Galen Buckwalter drove 15 minutes from his home to the California Institute of Technology, steered his wheelchair into a laboratory and, as he had twice a week for two years, plugged in his brain. More precisely, he allowed a researcher to attach wires to three metal knobs screwed into his skull like a cyberpunk mohawk. The wires connect to six chips that were implanted in his brain during a seven-hour craniotomy. They record his neural signals — the firing of his brain when he thinks, speaks or moves — and transmit them to a computer to be analyzed. (Wang, 11/17)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, November 18
  • Tuesday, November 17
  • Monday, November 16
  • Friday, November 13
  • Thursday, November 12
  • Tuesday, November 10
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF